Acamprosate controlled-release - Synchroneuron

Drug Profile

Acamprosate controlled-release - Synchroneuron

Alternative Names: Acamprosate calcium controlled-release tablet; Calcium N-acetylhomotaurinate; SNC-102

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synchroneuron
  • Class Alkanesulfonic-acids; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Drug-induced dyskinesia; Gilles de la Tourette's syndrome
  • Phase I Post-traumatic stress disorders

Most Recent Events

  • 14 Apr 2016 Synchroneuron withdraws a phase IIa trial for Post traumatic stress disorder in USA (NCT02384369)
  • 01 Feb 2016 Synchroneuron completes a phase II trial for Gilles de la Tourette syndrome in USA (NCT02217007)
  • 18 Jan 2016 Phase-I clinical trials in Post-traumatic stress disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top